| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3883081 | The Journal of Urology | 2019 | 5 Pages |
Abstract
Subcutaneous depot formulations of avorelin were well tolerated and had protracted inhibitory effects on pituitary gonadotropin secretion in patients with prostate cancer. Testosterone suppression was maintained for more than 6 months in all patients. Avorelin depots could be the first luteinizing hormone-releasing hormone agonist formulation to be administered at 6-month intervals.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
AMIR V. KAISARY, WINSOR G. BOWSHER, DAVID A. GILLATT, JOHN B. ANDERSON, PETER R. MALONE, BRUNO P. IMBIMBO, THE AVORELIN STUDY GROUP THE AVORELIN STUDY GROUP,